Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-2

Pralmorelin, Growth Hormone Releasing Peptide-2, KP-102

Quick Stats
Studies 230
Trials 1
Score 2
1999 pubmed

Growth hormone-releasing peptide-2 infusion synchronizes growth hormone, thyrotrophin and prolactin release in prolonged critical illness.

Van den Berghe. G G; Wouters. P P; Bowers. C Y CY; de Zegher. F F; Bouillon. R R; Veldhuis. J D JD

Key Findings

  • Prolonged critical illness disrupts the normal nightly pulsatile release of GH, TSH, and prolactin.
  • Continuous infusion of GHRP‑2 restores synchronized secretion of all three hormones (GH, TSH, PRL).
  • GHRH or TRH alone do not synchronize these hormones, and adding them to GHRP‑2 only preserves GH‑PRL synchrony, not the full trio.

Practical Outcomes

  • For biohackers, the study hints that GHRP‑2 can affect multiple pituitary hormones at once, but the data come from critically ill patients under controlled infusion, not healthy people. It’s not a ready‑to‑use protocol for longevity or performance, and more research is needed before applying GHRP‑2 for hormone coordination in everyday settings.

Summary

In very sick patients who stay in the ICU for a long time, their normal nightly bursts of growth hormone, thyroid‑stimulating hormone and prolactin disappear. Giving a steady infusion of the peptide GHRP‑2 at night made these three hormones start releasing together again, something that didn’t happen with other hormone‑stimulating drugs.

Abstract

During prolonged critical illness, nocturnal pulsatile secretion of GH, TSH and prolactin (PRL) is uniformly reduced but remains responsive to the continuous infusion of GH secretagogues and TRH. Whether such (pertinent) secretagogues would synchronize pituitary secretion of GH, TSH and/or PRL is not known. We explored temporal coupling among GH, TSH and PRL release by calculating cross-correlation among GH, TSH and PRL serum concentration profiles in 86 time series obtained from prolonged critically ill patients by nocturnal blood sampling every 20 min for 9 h during 21-h infusions of either placebo (n=22), GHRH (1 microg/kg/h; n=10), GH-releasing peptide-2 (GHRP-2; 1 microg/kg/h; n=28), TRH (1 microg/kg/h; n=8) or combinations of these agonists (n=8). The normal synchrony among GH, TSH and PRL was absent during placebo delivery. Infusion of GHRP-2, but not GHRH or TRH, markedly synchronized serum profiles of GH, TSH and PRL (all P< or =0.007). After addition of GHRH and TRH to the infusion of GHRP-2, only the synchrony between GH and PRL was maintained (P=0.003 for GHRH + GHRP-2 and P=0.006 for TRH + GHRH + GHRP-2), and was more marked than with GHRP-2 infusion alone (P=0.0006 by ANOVA). The nocturnal GH, TSH and PRL secretory patterns during prolonged critical illness are herewith further characterized to include loss of synchrony among GH, TSH and PRL release. The synchronizing effect of an exogenous GHRP-2 drive, but not of GHRH or TRH, suggests that the presumed endogenous GHRP-like ligand may participate in the orchestration of coordinated anterior pituitary hormone release.

Study Information

Provider

pubmed

Year

1999

DOI

10.1530/eje.0.1400017